Evidence map›Paper›PMID 28352616›Full record

ReviewProstate international2017

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand.

Bannakij Lojanapiwat, Choosak Pripatnanont, Vorapot Choonhaklai, Surithorn Soontornpun, Supon Sriplakich, Sunai Leewansangtong, Apirak Santi-Ngamkun, Julin Opanuraks, Wisoot Kongcharoensombat, Bhapapak Na-Songkla and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Prostate international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bannakij LojanapiwatDivision of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Choosak PripatnanontUrological Unit, Department of Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Vorapot ChoonhaklaiDivision of Urology, Department of Surgery, Rajavithi Hospital, Bangkok, Thailand.
Surithorn SoontornpunDivision of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Supon SriplakichDivision of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Sunai LeewansangtongDivision of Urology, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.
Apirak Santi-NgamkunDivision of Urology, Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Julin OpanuraksDivision of Urology, Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Wisoot KongcharoensombatDivision of Urology, Department of Surgery, Ramathibodi Hospital, Bangkok, Thailand.
Bhapapak Na-SongklaDivision of Urology, Department of Surgery, Faculty of Medicine, Navamindrathiraj University, Bangkok, Thailand.
Wiroj RaksakulDivision of Urology, Department of Surgery, Faculty of Medicine, Navamindrathiraj University, Bangkok, Thailand.
Chagkrapan PredanonUrological Unit, Department of Surgery, Khon Kaen Hospital, Khon Kaen, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment options for castration-resistant prostate cancer (CRPC) are available, but clear instructions for the selection of appropriate treatment are lacking. A meeting of urology experts based in Thailand was convened with the following objectives: (1) to reach a consensus and share real-life experiences about how to identify CRPC; (2) to choose the appropriate treatment for CRPC patients; (3) to evaluate disease progression using novel inhibitors of the androgen receptor pathway; (4) to identify the frequency of monitoring disease; and (5) to promote rational use of corticosteroids in CRPC patients. This consensus document can provide guidance to other urologists in Thailand to provide appropriate treatment to metastatic CRPC patients in a timely manner.

Indexed as

Abiraterone acetateAndrogen receptorMetastatic castration-resistant prostate cancerProstate-specific antigenUrology expert

Identifiers

PMID28352616
PMCPMC5357973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.